Revenue
2023
2024
2025
Immunome Inc. (IMNM)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — | — | — |
| Research & development | $177.3M | $129.5M | $23.1M | $23.3M | $14.1M | $7.5M | $8.8M |
| Operating expenses | $231.1M | $314.8M | $123.5M | $36.9M | $25.2M | $12.3M | $10.3M |
| Operating income | −$224.1M | −$305.8M | −$109.5M | −$36.9M | −$25.2M | −$12.3M | −$10.3M |
| EBITDAderived | −$221.6M | −$304.2M | −$109.1M | −$36.5M | −$24.4M | −$11.5M | −$9.7M |
| Net income | −$212.4M | −$293.0M | −$106.8M | −$36.9M | −$24.7M | −$17.8M | −$10.4M |
| Basic EPSper diluted share | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | -$9.55 |
| Diluted EPSper diluted share | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | -$9.55 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Lechleider RobertChief Medical Officer | SellCommon Stock | 14.4K | $20.66 | $297.9K | 15.8K |
| Jun 25, 2026Form 4 · 10b5-1 | Lechleider RobertChief Medical Officer | SellCommon Stock | 40.6K | $19.56 | $793.7K | 30.2K |
| Jun 15, 2026Form 4 · 10b5-1 | Rosett MaxChief Financial Officer | SellCommon Stock | 60.0K | $18.23 | $1.09M | 54.0K |
| Jun 5, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyCommon Stock | 1.0K | $19.27 | $19.3K | 43.4K |
| Jun 5, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyCommon Stock | 3.5K | $19.46 | $68.1K | 42.4K |